RxDoctor Payments Data

Andrew Wang, MD

Ophthalmology · Saint Joseph, MINPI 1992701098

Payments from drug & device makers

$421in general payments, 2019–2025

Across 16 payments — averaging $26.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$216
  • Merck$141
  • Novartis$64

What the payments were for

  • Food & beverage$421100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie2$216
Merck11$141
Novartis3$64

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$421 in reported general payments places this provider in the 30th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$299,468
Medicare patients
786
Services billed
3,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine28$18,625
LumiganBimatoprost60$18,557
Latanoprost814$7,672
Cyclosporine16$6,728
Prednisolone Acetate181$6,475
RhopressaNetarsudil Mesylate16$5,525
Brimonidine Tartrate115$3,484
Timolol Maleate233$3,030
Dorzolamide Hcl104$1,890
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat49$888
Fluorometholone13$860
Acyclovir42$657
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha40$516
Cromolyn Sodium26$489
ErythromycinErythromycin Base33$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$216$37,18288 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Saint Joseph

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →